Fibrocell Science, Inc. Receives Gold Award for LAVIV™ from Prestigious 2012 Golden Bridge Awards Program
EXTON, Pa.--(BUSINESS WIRE)-- Fibrocell Science, Inc. announced LAVIV™ (azficel-T) received the prestigious Gold Award in the "Lifestyle, Beauty and Fashions" Innovations category at the 4th Annual 2012 Golden Bridge Awards program. According to the San Francisco based organization, honorees are selected from an array of categories ranging from individuals to Gadget Innovations, such as the iPad which also received a Gold award. The awards were created to honor and generate industry-wide recognition of the achievements and positive contributions of organizations and businesses worldwide in every area.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB:FCSC.OB) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science, Inc. is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
About the Golden Bridge Awards
Golden Bridge Business and Innovation Awards are an annual industry and peers recognition program honoring best companies in every major industry from large to small and new start-ups in North America, Europe, Middle-East, Africa, Asia-Pacific, and Latin-America, Best New Products and Services, Best Innovations, Management and Teams, Women in Business and the Professions, Case Studies, Customer Satisfaction, and PR and Marketing Campaigns from all over the world. Learn more about The Golden Bridge Awards at www.goldenbridgeawards.com.
KEYWORDS: United States North America California Pennsylvania
The article Fibrocell Science, Inc. Receives Gold Award for LAVIV™ from Prestigious 2012 Golden Bridge Awards Program originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.